HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pharmacologic cholinesterase inhibition improves survival in acetaminophen-induced acute liver failure in the mouse.

AbstractBACKGROUND:
Acetaminophen (APAP) is one of the most widely used analgesic and antipyretic pharmaceutical substances in the world and accounts for most cases of drug induced liver injury resulting in acute liver failure. Acute liver failure initiates a sterile inflammatory response with release of cytokines and innate immune cell infiltration in the liver. This study investigates, whether pharmacologic acetylcholinesterase inhibition with neostigmine diminishes liver damage in acute liver failure via the cholinergic anti-inflammatory pathway.
METHODS:
Acute liver failure was induced in BALB/c mice by a toxic dose of acetaminophen (APAP). Neostigmine and/or N-acetyl-cysteine (NAC) were applied therapeutically at set time points and the survival was investigated. Liver damage was assessed by serum parameters, histopathology and serum cytokine assays 12 h after initiation of acute liver failure.
RESULTS:
Serum parameters, histopathology and serum cytokine assays showed pronounced features of acute liver failure 12 h after application of acetaminophen (APAP). Neostigmine treatment led to significant reduction of serum liver enzymes (LDH (47,147 ± 12,726 IU/l vs. 15,822 ± 10,629 IU/l, p = 0.0014) and ALT (18,048 ± 4,287 IU/l vs. 7,585 ± 5,336 IU/l, p = 0.0013), APAP-alone-treated mice vs. APAP + neostigmine-treated mice), inflammatory cytokine levels (IL-1β (147 ± 19 vs. 110 ± 25, p = 0.0138) and TNF-α (184 ± 23 vs. 130 ± 33, p = 0.0086), APAP-alone-treated mice vs. APAP + neostigmine-treated mice) and histopathological signs of damage.Animals treated with NAC in combination with the peripheral cholinesterase inhibitor neostigmine showed prolonged survival and improved outcome.
CONCLUSIONS:
Neostigmine is an acetylcholinesterase inhibitor that ameliorates the effects of APAP-induced acute liver failure in the mouse and therefore may provide new treatment options for affected patients.
AuthorsNiels Steinebrunner, Carolin Mogler, Spiros Vittas, Birgit Hoyler, Catharina Sandig, Wolfgang Stremmel, Christoph Eisenbach
JournalBMC gastroenterology (BMC Gastroenterol) Vol. 14 Pg. 148 (Aug 19 2014) ISSN: 1471-230X [Electronic] England
PMID25139304 (Publication Type: Journal Article)
Chemical References
  • Analgesics, Non-Narcotic
  • Cholinesterase Inhibitors
  • Free Radical Scavengers
  • IL1B protein, mouse
  • Interleukin-1beta
  • Tumor Necrosis Factor-alpha
  • Acetaminophen
  • Neostigmine
  • Lactate Dehydrogenases
  • Alanine Transaminase
  • Acetylcysteine
Topics
  • Acetaminophen (toxicity)
  • Acetylcysteine (pharmacology)
  • Alanine Transaminase (blood, drug effects)
  • Analgesics, Non-Narcotic (toxicity)
  • Animals
  • Chemical and Drug Induced Liver Injury (etiology, immunology, mortality)
  • Cholinesterase Inhibitors (pharmacology)
  • Disease Models, Animal
  • Free Radical Scavengers (pharmacology)
  • Interleukin-1beta (drug effects, immunology)
  • Lactate Dehydrogenases (blood, drug effects)
  • Liver (drug effects, immunology)
  • Liver Failure, Acute (chemically induced, immunology, mortality)
  • Mice
  • Mice, Inbred BALB C
  • Neostigmine (pharmacology)
  • Tumor Necrosis Factor-alpha (drug effects, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: